MEDIUMBuilt-inProduct / Revenue mix
46%
value-based contracts revenue
“10-K Item 1: 'In 2025, we generated more than 46% of our revenue from patients who are covered by value-based contracts.'”
TOI · Concentration risk · 10-K extracted
The Oncology Institute (TOI) concentration risks
Updated
The most significant concentration The Oncology Institute discloses is value-based contracts revenue at 46%, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: The Oncology Institute’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 4 disclosed concentrations
HIGH0
MEDIUM4
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partyCustomer
limited number of health insurance, IPA and medical group companies
“10-K Item 1A: 'A significant portion of our consolidated Patient Services revenue is derived from a limited number of health insurance, Independent Practice Associations, or IPAs and medical group companies.'”
MEDIUMOutside partyCustomer
a number of pharmacy benefit management companies
“10-K Item 1A: 'A significant portion of sales are from prescription drug sales reimbursed by a number of pharmacy benefit management companies with which TOI PCs contract.'”
MEDIUMBuilt-inGeographic
certain geographic areas
“10-K Item 1A: 'Our services are concentrated in certain geographic areas and populations exposing us to unfavorable changes in local benefit costs, reimbursement rates, competition and economic conditions.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06The Oncology Institute's concentration profile mixes business-model structure and counterparty dependency, but every disclosed exposure sits in the same medium-share band. On the revenue-model side, more than 46% of revenue comes from patients covered by value-based contracts — a structural feature of how the company gets paid rather than reliance on any single payor. Layered on top are two dependency exposures: a significant portion of Patient Services revenue flows through a limited number of health insurance companies, IPAs, and medical group companies, and prescription drug sales are reimbursed by a limited number of pharmacy benefit management companies. Neither discloses a specific concentration percentage, but both describe reliance on a narrow set of counterparties that intermediate payment. Finally, services are concentrated in certain geographic areas and populations, a structural exposure to local reimbursement rates, competition, and economic conditions. Taken together, these four medium-share exposures compound rather than offset each other: the value-based payment structure, the payor/PBM dependency, and the geographic concentration all touch the same revenue stream, so a shock to reimbursement policy or a regional payor relationship could affect a meaningful slice of the business at once.
For the engine’s reasoning on TOI’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Care Facilities
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACHC | Acadia Healthcare Company, Inc. | 1 | 1 | 0 | 2 |
| TOI● | The Oncology Institute, Inc. | 0 | 4 | 0 | 4 |
| ADUS | Addus HomeCare Corporation | 0 | 2 | 4 | 6 |
| ARDT | Ardent Health, Inc. | 0 | 2 | 0 | 2 |
| AMN | AMN Healthcare Services Inc | 0 | 0 | 1 | 1 |
| AGL | agilon health, inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.